Loading stock data…
FATE
$1.53+0.28 (+22.40%)
Market ClosedLast close May 1
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fate Therapeutics, Inc. in the Healthcare sector is trading at $1.53. The stock is currently 21% below its 52-week high of $1.94, remaining 29.7% above its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why FATE maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.53
Potential Upside
5%
Whystock Fair Value$1.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$5.19+239.1%
Range$2.00 – $8.00
Fundamentals
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$159.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-65.79%
Volume
Today's trading volume
5.00M
Recent News
Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference
Fate Therapeutics (NASDAQ:FATE) used a presentation at the Needham Healthcare Conference to outline its strategy for developing “off-the-shelf” CAR T-cell therapies, highlighting clinical progress in autoimmune disease with FT819 and early proof-of-concept signals in solid tumors with FT836. Preside
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference
Fate Therapeutics (NASDAQ:FATE) CEO Bob Valamehr outlined the company’s clinical and manufacturing strategy for FT819, an off-the-shelf allogeneic CAR T-cell therapy, during a conference fireside chat hosted by Leerink Partners senior equity research analyst Daina Graybosch. Valamehr emphasized that
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +1.21% and -8.73%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics: Q4 Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 27 cents. The results matched Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was also for a loss of 27 cents per share.
Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...